コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 motherapy with concurrent GV1001 (concurrent chemoimmunotherapy).
2 associated with poor outcomes after standard chemoimmunotherapy.
3 fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy.
4 0 engagement represents a novel and rational chemoimmunotherapy.
5 on has not been examined in CLL trials using chemoimmunotherapy.
6 ore be useful in predicting poor response to chemoimmunotherapy.
7 leukaemia with poor outcome after first-line chemoimmunotherapy.
8 q), appear to have a shorter PFS and OS with chemoimmunotherapy.
9 examined relative to treatment outcome with chemoimmunotherapy.
10 reatment with chemotherapy to treatment with chemoimmunotherapy.
11 oxicities were greater in patients receiving chemoimmunotherapy.
12 2 (range, 1-9), and 63% received >/=1 prior chemoimmunotherapy.
13 isk factors associated with poor response to chemoimmunotherapy.
14 aemia have poor responses and survival after chemoimmunotherapy.
15 n of disease (POD) within 2 years of initial chemoimmunotherapy.
16 tation have lower response rates to standard chemoimmunotherapy.
17 with TP53 mutations have lower responses to chemoimmunotherapy.
18 be able to receive anthracycline-containing chemoimmunotherapy.
19 s alemtuzumab or ibrutinib) seem better than chemoimmunotherapy.
20 n a PFS less than 36 months after first-line chemoimmunotherapy.
21 5 years, despite a low CMR rate (47%) after chemoimmunotherapy.
22 l (PFS <36 months) after previous first-line chemoimmunotherapy.
23 e additional treatment modality used, mainly chemoimmunotherapy.
24 itors, thereby opening new opportunities for chemoimmunotherapy.
25 phoma (FL) patients after a brief first-line chemoimmunotherapy.
26 received prior fludarabine-based therapy or chemoimmunotherapy.
27 ajority are instead observed or treated with chemoimmunotherapy.
28 olidation after high-dose-methotrexate-based chemoimmunotherapy.
29 cy with a median survival of 3 years despite chemoimmunotherapy.
30 orubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy.
31 n of conventional chemotherapy but not after chemoimmunotherapy.
32 ism contributing to the efficacy of combined chemoimmunotherapy.
33 kaemia with active disease, who responded to chemoimmunotherapy 2-5 months after completion of first-
36 with 17p13.1 deletion have poor response to chemoimmunotherapy and are treated differently, with som
37 a poor prognosis when treated with standard chemoimmunotherapy and have increased risk of central ne
38 cristine, dexamethasone (VcR-CVAD) induction chemoimmunotherapy and maintenance rituximab (MR) were e
39 rably at 6 to 8 weeks, after chemotherapy or chemoimmunotherapy, and 8 to 12 weeks after radiation or
40 rine analogs, short response [<24 months] to chemoimmunotherapy, and/or presence of del[17p]/TP53 mut
45 (MRD) at the end of induction treatment with chemoimmunotherapy as a surrogate end point for progress
50 exhibits high remission rates after initial chemoimmunotherapy, but with relapses with treatment, re
52 lymphoma/leukemia (BL) patients treated with chemoimmunotherapy can be verified outside published ser
53 volving management of CLL from 2011 to 2025: chemoimmunotherapy (CIT) as the standard of care before
55 Bruton tyrosine kinase, were evaluated with chemoimmunotherapy (CIT) in a multicenter phase 1b study
56 est toxicity, indicating suitability of this chemoimmunotherapy (CIT) platform for combination with i
57 ree survival can be achieved with first-line chemoimmunotherapy (CIT), such as combined fludarabine,
63 se of MATRix combination as the new standard chemoimmunotherapy for patients aged up to 70 years with
64 ents received donor lymphocyte infusions +/- chemoimmunotherapy for relapse, and five patients obtain
65 to the inclusion of anthracycline in upfront chemoimmunotherapy for these elderly patients and highli
66 he chemotherapy group than in the sequential chemoimmunotherapy group (7.9 months [95% CI 7.1-8.8] vs
67 CI 0.97-1.48, p=0.05), or in the concurrent chemoimmunotherapy group (8.4 months [95% CI 7.3-9.7], H
70 herapy group, and 44 [12%] in the concurrent chemoimmunotherapy group); and pain (34 [9%] patients in
71 he chemotherapy group, 350 to the sequential chemoimmunotherapy group, and 354 to the concurrent chem
72 emotherapy group, 39 [11%] in the sequential chemoimmunotherapy group, and 41 [12%] in the concurrent
73 emotherapy group, 35 [10%] in the sequential chemoimmunotherapy group, and 44 [12%] in the concurrent
74 y group, 58 [17%] patients in the sequential chemoimmunotherapy group, and 79 [22%] patients in the c
75 oup, and 79 [22%] patients in the concurrent chemoimmunotherapy group; fatigue (27 [8%] in the chemot
79 rituximab to standard chemotherapy regimens (chemoimmunotherapy) improves both response rates and sur
84 therapies after high-dose methotrexate-based chemoimmunotherapy in patients aged 70 years or younger
85 nase (BTK) inhibitor ibrutinib, with classic chemoimmunotherapy in patients with chronic lymphocytic
86 ts a potential option as consolidation after chemoimmunotherapy in patients with diffuse large B-cell
89 -M after FCR argues for the continued use of chemoimmunotherapy in this patient subgroup outside clin
90 as consolidation after front-line induction chemoimmunotherapy in untreated elderly patients with di
94 e long-progression-free survival (PFS) after chemoimmunotherapy is essential given the availability o
97 HBV infection and suggest that such combined chemoimmunotherapy may be useful for treatment of humans
98 on treatment failure from large trials using chemoimmunotherapy may help to define risk groups in CLL
100 These data show a novel strategy of combined chemoimmunotherapy of cancer targeting a CTA induced de
102 motherapy with sequential GV1001 (sequential chemoimmunotherapy), or chemotherapy with concurrent GV1
107 and with rituximab plus high-dose sequential chemoimmunotherapy (R-HDS) in relapsed aggressive lympho
108 ive ALL did not benefit from rituximab-based chemoimmunotherapy (rates of CRD 45% v 50%, P = NS and O
110 gues, monoclonal antibodies, and combination chemoimmunotherapy regimens) have dramatically improved
111 atients are eligible for aggressive up-front chemoimmunotherapy regimens, so what is the optimal trea
114 P53 aberrations respond poorly to first-line chemoimmunotherapy, resulting in early relapse and short
116 patients achieved a complete remission after chemoimmunotherapy, seven of whom were MRD negative.
117 is in these conditions and suggest effective chemoimmunotherapy strategies using this new generation
118 y of these diseases with the introduction of chemoimmunotherapy that may finally result in improvemen
119 yet universal approach termed "chemocentric chemoimmunotherapy" that has potential application in th
121 ded approach to therapy, including choice of chemoimmunotherapy, the role of stem-cell transplantatio
123 We report the long-term follow-up of the chemoimmunotherapy trial CALGB 9712 from the Cancer and
125 randomized chemotherapy, immunotherapy, and chemoimmunotherapy trials demonstrates that CR30 is a su
127 POT1 as novel determinants of outcome after chemoimmunotherapy using chlorambucil and anti-CD20 trea
129 predictive factor for all three end points; chemoimmunotherapy was the superior treatment regimen.
130 onse after four or more cycles of first-line chemoimmunotherapy, were eligible if they had high minim
134 tomatic, untreated CLL patients who received chemoimmunotherapy with fludarabine and rituximab as par
135 spite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (F
139 The efficacy, toxicity, and tolerability of chemoimmunotherapy with the combination of fludarabine,
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。